TrialSpark is a technology-driven pharma company that runs end-to-end clinical trials, focused on bringing new treatments to patients faster and more efficiently. TrialSpark has built a technology platform that optimizes all aspects of a clinical trial, enabling more efficient trial design, faster trial completion, and higher trial data quality. TrialSpark in-licenses and co-develops drug programs through in-house development, joint ventures, and NewCos.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
09/30/21	$156,000,000	Series C	ArrowMark Partners Casdin Capital Dragoneer Investment Group Felicis Ventures John Doerr Lachy Groom Sam Altman Section 32 Sound Ventures Spark Capital Thrive Capital	undisclosed